Keywords
cannabinoids
medical marijuana
knowledge
students
How to Cite
Abstract
Introduction: Cannabis sativa (marijuana) contains approximately 60 cannabinoids, of which, delta-9-tetrahydrocannabinol is the most studied component to be used for medicinal purposes. Adequate knowledge by citizens of this therapeutic strategy is a key process to guarantee the acceptance and the good adherence to the treatment. Objective: To establish the perception of undergraduate students of Pharmaceutical Chemistry, Technology in Regency of pharmacy and medicine of the University of Antioquia, as regards to the use of cannabis extracts products as medicinal treatment. Method: Observational cross-sectional study, based on surveys to students through an online form. Results: 374 surveys were obtained, 232 (62%) from students of Pharmaceutical Chemistry and Technology in Regency of Pharmacy, and 142 (38%) from Medicine. 222 (59.4%) of the students were female, with a mean age of 22.5 years, and 348 (94%) live in low and middle socioeconomic strata. It was found that students claim to have inadequate knowledge regarding the use of medical marijuana, the use of medicinal cannabinoids, regulation and safety. Related to the opinion of the medicinal use, 356 (95.2%) respondents agreed. Conclusions: Most of the students report inadequate knowledge about the use of therapeutic cannabinoids. In addition, most students agree with the use of medical marijuana.
References
2. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007; 4(8): 1614-1648. doi: 10.1002/cbdv.200790144.
3. Rodríguez Carranza R. Los productos de Cannabis sativa: situación actual y perspectivas en medicina. Salud Ment. 2012; 35(3): 247-256.
4. Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag. 2001; 6(2): 80-91.
5. Parmar JR, Forrest BD, Freeman RA. Medical marijuana patient counseling points for health care professionals based on trends in the medical uses, efficacy, and adverse effects of cannabis-based pharmaceutical drugs. Res Soc Adm Pharm. 2016; 12(4): 638-654. doi: 10.1016/j.sapharm.2015.09.002.
6. Brenneisen R. Chemistry and analysis of Phytocannabinoids and other Cannabis Constituents. En: ElSohly MA, editor. Marijuana and the Cannabinoids. Totowa, NJ: Humana Press; 2007. 17-49.
7. ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci. 2005; 78(5): 539-548. doi:10.1016/j.lfs.2005.09.011.
8. Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001; 56(11): 1059-1068.
9. Instituto Nacional de Vigilancia de Medicamentos y Alimentos. Primer paso para comercializar producto de extractos de cannabis en Colombia. Comunicado de Prensa. Bogotá. 2016.
10. Senado de la República Colombia. Proyecto de ley 80 de 2014, “Por medio del cual se reglamenta el Acto Legislativo 02 de 2009”. Imprenta Nacional de Colombia. 2016.
11. Ministerio de Salud y Protección Social. Decreto 613 del 10 de abril de 2017, “Por el cual se reglamenta la Ley 1787 de 2016 y se subroga el Título 11 de la Parte 8 del Libro 2 del Decreto 780 de 2016, en relación con el acceso seguro e informado al uso médico y científico del cannabis”. Colombia.
12. Belendiuk KA, Baldini LL, Bonn-Miller MO. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015; 10(1): 10. doi: 10.1186/s13722-015-0032-7.
13. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry. 2001; 178(2): 107-115.
14. Lemberger L, Rowe H. Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharmacol Ther. 1975; 18(6): 720-726.
15. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979; 300(23): 1295-1297. doi: 10.1056/NEJM197906073002302.
16. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991; 40(3): 695-700.
17. Beal JE, Olson R, Laubenstein L, Morales JO, Bellman P, Yangco B, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995; 10(2): 89-97.
18. Syed YY, McKeage K, Scott LJ. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs. 2014; 74(5): 563-578. doi: 10.1007/s40265-014-0197-5.
19. Flachenecker P, Henze T, Zettl UK. Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice-results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity. Eur Neurol. 2014;71(5-6): 271-279. doi: 10.1159/000357427.
20. Sexton M, Cuttler C, Finnell JS, Mischley LK. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016; 1(1): 131-138. doi: 10.1089/can.2016.0007.
21. Kerlin AM, Long M, Kappelman M, Martin C, Sandler RS. Profiles of Patients Who Use Marijuana for Inflammatory Bowel Disease. Dig Dis Sci. 2018; 63(6): 1600-1604. doi: 10.1007/s10620-018-5040-5.
22. Furler MD, Einarson TR, Millson M, Walmsley S, Bendayan R. Medicinal and recreational marijuana use by patients infected with HIV. AIDS Patient Care STDS. 2004; 18(4): 215-228. doi: 10.1089/108729104323038892.
23. Pacek LR, Towe SL, Hobkirk AL, Nash D, Goodwin RD. Frequency of Cannabis use and medical Cannabis use among persons living with HIV in the United States: Findings from a Nationally Representative Sample. AIDS Educ Prev. 2018; 30(2): 169-181. doi: 10.1521/aeap.2018.30.2.169.
24. Copeland J, Todd S, Gates P. Survey of australians knowledge, perception and use of cannabis for medicinal purposes. J Addiction Prevention. 2016; 5(1):10.
25. Gaviria A. La marihuana con uso terapéutico en el contexto colombiano. Ministro de Salud y Protección Social. Bogotá; 2014.
26. Ortiz M, Ortiz E. Psicología de la salud: una clave para comprender el fenómeno de la adherencia terapéutica. Rev Med Chil. 2007; 135(5): 647-652. http://dx.doi.org/10.4067/S0034-98872007000500014.
27. Universidad de Chile. Investigación Percepciones sobre el Proyecto Genoma Humano Instrumento 20/03 Sociedad Civil-Estudiantes.
28. González O, González M del R, Yeverino ML, Gracia SL, Gracia YA. Actitudes hacia el consumo de marihuana medicinal en estudiantes de la carrera de Químico Farmacéutico Biólogo de la Universidad Autónoma de Nuevo León. Ars Pharm. 2016; 57(Suppl 1): 107-108.
29. Moeller KE, Woods B. Pharmacy students’ knowledge and attitudes regarding medical marijuana. Am J Pharm Educ. 2015; 79(6): 85. doi: 10.5688/ajpe79685.
30. Vujcic I, Pavlovic A, Dubljanin E, Maksimovic J, Nikolic A, Sipetic-Grujicic S. Attitudes toward medical Cannabis legalization among Serbian medical students. Subst Use Misuse. 2017; 52(9): 1229-1235. doi: 10.1080/10826084.2017.1302959.
Se autoriza la reproducción total o parcial de la obra para fines educativos, siempre y cuando se cite la fuente.
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Pública Internacional.